Regression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.

Regression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.

Mostrar otras versiones (1)

Preschool children suffer from morbidity attributable to Schistosoma mansoni. We compared a single and double dose of praziquantel treatment on the regression of S. mansoni associated morbidity in children less than six years in Uganda. We measured the sizes of spleen and liver as well as liver fibr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Allen Nalugwa, Edridah Muheki Tukahebwa, Annette Olsen, Fred Nuwaha
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/4e4c2668b9fb41b5aa2bbc70d92092d8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4e4c2668b9fb41b5aa2bbc70d92092d8
record_format dspace
spelling oai:doaj.org-article:4e4c2668b9fb41b5aa2bbc70d92092d82021-12-02T20:13:10ZRegression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.1932-620310.1371/journal.pone.0259338https://doaj.org/article/4e4c2668b9fb41b5aa2bbc70d92092d82021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259338https://doaj.org/toc/1932-6203Preschool children suffer from morbidity attributable to Schistosoma mansoni. We compared a single and double dose of praziquantel treatment on the regression of S. mansoni associated morbidity in children less than six years in Uganda. We measured the sizes of spleen and liver as well as liver fibrosis before treatment and 8 months after treatment among children who either received one dose (n = 201) or two doses (n = 184) of praziquantel (standard oral dose of 40 mg/kg body weight). Heamoglobin measurements were also taken. Overall, liver enlargement reduced from 52.2% (95% CI (Confidence interval) 45.1, 59.3) to 17.9% (95% CI 12.9, 23.9) with a single dose and from 48.4 (95% CI 40.9, 55.8) to 17.9% (95% CI 12.7, 24.3) with a double dose and there was no significant difference between the changes in proportion of children with enlarged liver between the two treatment groups. The proportion of children with enlarged spleen was not significantly reduced in the group treated with either one or two doses, 47.8% (95% CI 41.7, 54.9) to 45.3% (95% CI 38.3, 52.4) and 48.4% (95% CI 40.9,55.8) to 40.8% 95% CI 33.6, 48.2), respectively. Liver fibrosis detected among children getting single dose (n = 9) or double doses (n = 13) resolved after treatment with praziquantel. The number of children with low heamoglobin significantly reduced from 51.2% (95% CI 44.1, 58.3) to 0.5% (0.2, 0.8) and 61.4% (95% CI 53.9,68.5) to 1.1% (95% CI 0.1, 3.9) after single and double dose treatment, respectively. These results suggest that there is no evidence of a difference in effect between one dose of praziquantel and two doses in reversing morbidity attributable to S. mansoni among children less than six years of age.Allen NalugwaEdridah Muheki TukahebwaAnnette OlsenFred NuwahaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0259338 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Allen Nalugwa
Edridah Muheki Tukahebwa
Annette Olsen
Fred Nuwaha
Regression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.
description Preschool children suffer from morbidity attributable to Schistosoma mansoni. We compared a single and double dose of praziquantel treatment on the regression of S. mansoni associated morbidity in children less than six years in Uganda. We measured the sizes of spleen and liver as well as liver fibrosis before treatment and 8 months after treatment among children who either received one dose (n = 201) or two doses (n = 184) of praziquantel (standard oral dose of 40 mg/kg body weight). Heamoglobin measurements were also taken. Overall, liver enlargement reduced from 52.2% (95% CI (Confidence interval) 45.1, 59.3) to 17.9% (95% CI 12.9, 23.9) with a single dose and from 48.4 (95% CI 40.9, 55.8) to 17.9% (95% CI 12.7, 24.3) with a double dose and there was no significant difference between the changes in proportion of children with enlarged liver between the two treatment groups. The proportion of children with enlarged spleen was not significantly reduced in the group treated with either one or two doses, 47.8% (95% CI 41.7, 54.9) to 45.3% (95% CI 38.3, 52.4) and 48.4% (95% CI 40.9,55.8) to 40.8% 95% CI 33.6, 48.2), respectively. Liver fibrosis detected among children getting single dose (n = 9) or double doses (n = 13) resolved after treatment with praziquantel. The number of children with low heamoglobin significantly reduced from 51.2% (95% CI 44.1, 58.3) to 0.5% (0.2, 0.8) and 61.4% (95% CI 53.9,68.5) to 1.1% (95% CI 0.1, 3.9) after single and double dose treatment, respectively. These results suggest that there is no evidence of a difference in effect between one dose of praziquantel and two doses in reversing morbidity attributable to S. mansoni among children less than six years of age.
format article
author Allen Nalugwa
Edridah Muheki Tukahebwa
Annette Olsen
Fred Nuwaha
author_facet Allen Nalugwa
Edridah Muheki Tukahebwa
Annette Olsen
Fred Nuwaha
author_sort Allen Nalugwa
title Regression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.
title_short Regression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.
title_full Regression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.
title_fullStr Regression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.
title_full_unstemmed Regression of Schistosoma mansoni associated morbidity among Ugandan preschool children following praziquantel treatment: A randomised trial.
title_sort regression of schistosoma mansoni associated morbidity among ugandan preschool children following praziquantel treatment: a randomised trial.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/4e4c2668b9fb41b5aa2bbc70d92092d8
work_keys_str_mv AT allennalugwa regressionofschistosomamansoniassociatedmorbidityamongugandanpreschoolchildrenfollowingpraziquanteltreatmentarandomisedtrial
AT edridahmuhekitukahebwa regressionofschistosomamansoniassociatedmorbidityamongugandanpreschoolchildrenfollowingpraziquanteltreatmentarandomisedtrial
AT annetteolsen regressionofschistosomamansoniassociatedmorbidityamongugandanpreschoolchildrenfollowingpraziquanteltreatmentarandomisedtrial
AT frednuwaha regressionofschistosomamansoniassociatedmorbidityamongugandanpreschoolchildrenfollowingpraziquanteltreatmentarandomisedtrial
_version_ 1718374822807863296

Ejemplares similares